Researchers have developed a genome-editing strategy that targets a common cause of roughly 30 percent of rare diseases and could vastly improve access to gene-editing treatments for patients.
Stimulating the liver to produce some of the signals of the thymus can reverse age-related declines in T-cell populations and enhance response to vaccination.
Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder that begins in infancy.
The Ó³»´«Ã½ core member and gene editing pioneer describes a framework that could enable the treatment of 1,000 patients with personalized gene editing therapies by 2030.
Ó³»´«Ã½ scientists describe how data resources they helped build over more than a decade now form the foundation for cutting-edge AI and genome biology discoveries.
Large analysis of genes and proteins in lung adenocarcinoma points to possible new diagnostic and treatment approaches, and also reveals signatures of chemical exposures in patients who have never smoked.
Test of circulating tumor cells offers less invasive option for multiple myeloma surveillance, staging, and biological study compared to bone marrow biopsies
Developed in collaboration with Ó³»´«Ã½ Clinical Labs and Mass General Brigham Laboratory for Molecular Medicine, the test provides a comprehensive view of a patient’s inherited heart disease risk.
Researchers double the number of genetic factors associated with this common arrhythmia, highlighting biological pathways that could be targeted by new medicines.
Making single-letter edits in stretches of repeated DNA stopped or reversed the genetic change that causes Huntington’s disease and Friedreich’s ataxia.
Combining powerful imaging, perturbational screening, and machine learning, researchers uncover new human host factors that alter Ebola’s ability to infect.
In several papers published this week in Nature, Nature Genetics, PLoS Biology and Genome Research, Ó³»´«Ã½ researchers and an international set of collaborators announce substantial advances in relating human genetic variation to disease and understanding human evolutionary history.
It is my great pleasure to share with you some of the exciting results presented in the paper published today in Nature, describing the data and analysis of Phase I of the HapMap Project. I first want to share a few personal thoughts as a physician and scientist about why so many of us choose to spend our professional lives studying DNA variation and its role in human health.
"Not chaos — like together crush'd and bruis'd,
But as the world, harmoniously confus'd,
Where order in variety we see,
And where, though all things differ, all agree."